2 A therapeutic agent comprising lipocalin 2 against cancer metastasis and methods of early diagnosis and inhibition of cancer metastasis using lipocalin 2

摘要

The present invention relates to a pharmaceutical composition for inhibiting cancer metastasis, and more specifically, a lipocalin 2 protein, a gene encoding the same, an expression vector including the gene or a cell transduced with the expression vector as an active ingredient. The present invention relates to a pharmaceutical composition for inhibiting cancer metastasis, a method for inhibiting cancer metastasis using the same, a kit for predicting cancer metastasis, and a method for selecting a cancer metastasis risk group using the kit. The pharmaceutical composition of the present invention can significantly improve the anticancer therapeutic effect by specifically inhibiting cancer metastasis, and the method for screening cancer metastasis risk group using the predictive kit and the kit of the present invention is lipocalin in cancer tumor tissues or body fluids. By examining 2 expressions, a risk group with a high risk of metastasis can be selected, which can be usefully used in the management of cancer patients in actual clinical practice.;Lipocalin 2, NGAL, prognostic factor, transfer inhibitor.